Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum β-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)

Antimicrobial Agents and Chemotherapy
2010.0

Abstract

From 2002 to 2008, there was a significant increase in extended-spectrum beta-lactamase (ESBL)-positive Escherichia coli isolates in European intra-abdominal infections, from 4.3% in 2002 to 11.8% in 2008 (P < 0.001), but not for ESBL-positive Klebsiella pneumoniae isolates (16.4% to 17.9% [P > 0.05]). Hospital-associated isolates were more common than community-associated isolates, at 14.0% versus 6.5%, respectively, for E. coli (P < 0.001) and 20.9% versus 5.3%, respectively, for K. pneumoniae (P < 0.01). Carbapenems were consistently the most active drugs tested.

DOI： 10.1128/aac.00265-10

Knowledge Graph

Similar Paper

Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum β-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)
Antimicrobial Agents and Chemotherapy 2010.0
Emergence of High Levels of Extended-Spectrum-β-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007
Antimicrobial Agents and Chemotherapy 2009.0
Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)
Antimicrobial Agents and Chemotherapy 2010.0
Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-β-Lactamase-Producing and Acquired AmpC β-Lactamase-Producing Escherichia coli Isolates from Canadian Intensive Care Units
Antimicrobial Agents and Chemotherapy 2008.0
Surveillance of Community-Based Reservoirs Reveals the Presence of CTX-M, Imported AmpC, and OXA-30 β-Lactamases in Urine Isolates of Klebsiella pneumoniae and Escherichia coli in a U.S. Community
Antimicrobial Agents and Chemotherapy 2008.0
Molecular Characterization and Epidemiology of Extended-Spectrum- β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Isolates Causing Health Care-Associated Infection in Thailand, Where the CTX-M Family Is Endemic
Antimicrobial Agents and Chemotherapy 2008.0
Characterization and Sequence Analysis of Extended-Spectrum-β-Lactamase-Encoding Genes from Escherichia coli, Klebsiella pneumoniae , and Proteus mirabilis Isolates Collected during Tigecycline Phase 3 Clinical Trials
Antimicrobial Agents and Chemotherapy 2009.0
KPC-Producing Extreme Drug-Resistant Klebsiella pneumoniae Isolate from a Patient with Diabetes Mellitus and Chronic Renal Failure on Hemodialysis in South Korea
Antimicrobial Agents and Chemotherapy 2010.0
Microbiologic and Clinical Implications of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae with or without Plasmid-Mediated AmpC β-Lactamase DHA-1
Antimicrobial Agents and Chemotherapy 2010.0
Emergence of Serratia marcescens , Klebsiella pneumoniae , and Escherichia coli Isolates Possessing the Plasmid-Mediated Carbapenem-Hydrolyzing β-Lactamase KPC-2 in Intensive Care Units of a Chinese Hospital
Antimicrobial Agents and Chemotherapy 2008.0